Search Results - cancer+therapeutics

61 Results Sort By:
Enhanced Combinatorial Oncolytic Virotherapy
Oncolytic viruses (OVs) are able to selectively infect and kill cancer cells without damaging normal cells. They can be used as a monotherapy, or they can be combined with existing cancer therapeutics for increased potency. While much progress has been made around OVs, one of their biggest limitations is their inability to successfully replicate, spread,...
Published: 3/31/2025   |   Inventor(s): Mohammed Masmudur Rahman
Keywords(s):  
Category(s): Cancer, Cancer Therapeutics, Life Science (All LS Techs), Pharmaceuticals
Neutrophil based CAR Therapies for Treatment
Chimeric antigen receptor (CAR)-T-cell-based immunotherapies have dramatically improved survival in cancer patients. Unfortunately, CAR-T cell therapies are associated with severe neurotoxicity, adverse events during clinical trials, and cytokine storm syndrome among others. Therefore, there is a great need to develop strategies that can keep the benefits...
Published: 2/19/2025   |   Inventor(s): Abhinav Acharya, Mamta Wankhede
Keywords(s):  
Category(s): Advanced Materials/Nanotechnology, Biomaterials, Cancer, Cancer Therapeutics, Life Science (All LS Techs), Pharmaceuticals, Nucleic Acid/Peptide/Protein Therapies
Metabolite Delivery for Modulating Metabolic Pathways of Cells
There is a great need to deliver metabolites intracellularly without modifying the metabolite itself and rescue immune cells against metabolic exhaustion. In cancer therapy, metabolic pathway inhibitors are used that starve both cancerous cells as well as non-cancerous cells. Therefore, the ability to target specific immune cells and deliver metabolites...
Published: 2/19/2025   |   Inventor(s): Abhinav Acharya
Keywords(s):  
Category(s): Advanced Materials/Nanotechnology, Biomaterials, Cancer Therapeutics, Cancer, Life Science (All LS Techs), Pharmaceuticals, Nucleic Acid/Peptide/Protein Therapies
Central Carbon Metabolite Based Polymers for Immunotherapy
Inhibition of glycolysis or glutaminase pathway is an effective strategy to prevent cancer cell growth in vitro and in vivo. However, these pathways are also utilized by immune cells to mount responses against cancer cells, and therefore, utilizing, immunotherapies in the presence of such inhibitors is challenging. Thus, there is a need for technologies...
Published: 2/19/2025   |   Inventor(s): Abhinav Acharya, Sahil H Inamdar
Keywords(s):  
Category(s): Advanced Materials/Nanotechnology, Biomaterials, Cancer, Cancer Therapeutics, Life Science (All LS Techs), Nucleic Acid/Peptide/Protein Therapies, Pharmaceuticals
Rescue from Glycolysis and mRNA Based Vaccines
Glycolysis inhibition in cancer cells has long been recognized as a viable strategy to prevent cancer cell growth. Cancer cells are known to have a high glucose consumption rate as a metabolism adaptation mechanism called the Warburg effect. Activated immune cells also rely on glycolysis for their energy needs. For example, glycolysis is essential for...
Published: 2/19/2025   |   Inventor(s): Abhinav Acharya
Keywords(s):  
Category(s): Advanced Materials/Nanotechnology, Life Science (All LS Techs), Nucleic Acid/Peptide/Protein Therapies, Pharmaceuticals, Vaccines/Antimicrobials, Cancer, Cancer Therapeutics, Biomaterials
Metabolically-fit Immunotherapies Portfolio
M23-139L – Inducing or Rescuing Glycolysis in Cancer Cells. Compositions that selectively block glycolysis in cancer cells while simultaneously enable glycolysis in non-cancer cells, such as macrophages, T cells, NK cells, etc. Vaccine formulations have been developed and tested on mice with positive results. Please see the published PCT (WO2024151709A1)...
Published: 2/13/2025   |   Inventor(s):  
Keywords(s):  
Category(s): Advanced Materials/Nanotechnology, Biomaterials, Biological Nanotechnology, Cancer, Cancer Therapeutics, Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals, Vaccines/Antimicrobials
Methods for Enhancing Production of Beneficial Short- and Medium- Chain Fatty Acids by the Gut Microbiome
Short-chain fatty acids (SCFAs) which include acetate (C2), propionate (C3) and butyrate (C4) are important, health-benefiting metabolites, produced when microbes in the human colon ferment polysaccharides and dietary fiber. Medium-chain fatty acids (MCFAs), such as caproate (C6) and caprylate (C8), have also been shown to provide health benefits and...
Published: 2/13/2025   |   Inventor(s): Anca Delgado, Rosa Krajmalnik-Brown, Dorsa Daeizadeh
Keywords(s):  
Category(s): Life Science (All LS Techs), Microbiome, Neurodegenerative Disease Technologies, Cancer, Cancer Therapeutics
Method for Repurposing FDA-approved Therapeutics & Composition for Treating Mesothelioma
The amount of time and money that goes into getting a drug from initial discovery to FDA approval is substantial, typically involving at least 10 years and hundreds of millions of dollars. Because of this, there has been a growing interest in repurposing drugs which have previously been approved for human use, particularly since their MOA as well as...
Published: 2/18/2025   |   Inventor(s): Chris Plaisier, Sierra Wilferd, Choung Hoang
Keywords(s): Cancer, Drug, Drug Discovery
Category(s): Pharmaceuticals, Cancer, Cancer Therapeutics, Artificial Intelligence/Machine Learning, Computing & Information Technology, Life Science (All LS Techs)
Novel Human C3 Derivatives for Therapeutic Complement Depletion
The complement system is part of the immune system and is important in both innate and adaptive immunity. However, the complement system can also be a pathogenetic factor in many diseases including, rheumatoid arthritis, reperfusion injury, myasthenia gravis, and more. Complement has also been shown to be important for the development of antibodies...
Published: 2/13/2025   |   Inventor(s): Carl-Wilhelm Vogel, Paul Finnegan, Julie Rayes, Sebastien Lacroix-Desmazes
Keywords(s):  
Category(s): Cancer Therapeutics, Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
RNA Sensor Platform for Targeting Cancer Fusion Genes and Transcripts
Many cancers have recurrent chromosomal translocations leading to the fusion of two genes. Often, said cancers are aggressive, have a poor prognosis with metastasis or recurrence, and do not have effective and targeted treatment. The challenge of many fusion-positive cancers is the lack of established targets downstream of the gene fusion despite years...
Published: 2/13/2025   |   Inventor(s): Albert Cheng, Ching Lau, Nathaniel Jilette, Jacqueline Jufen Zhu
Keywords(s):  
Category(s): Cancer, Cancer Therapeutics, Chemical/Biological Sensors, Genomic Assays/Reagents/Tools, Life Science (All LS Techs)
1 2 3 4 5 6 7